Induction outcome of Acute Lymphoblastic Leukemia at a single pediatric oncology centre of CCTH

Abstract

Background: Acute lymphoblastic leukaemia (ALL), it’s clonal proliferation and accumulation of lymphoblast in blood, bone marrow and other organs. Objective: Evaluate of newly diagnosed ALL patients over three years, for their characters, risk groups and induction outcome Patients and Method: A prospective study included, (240) children below the age of 15 years with newly diagnosed ALL-LI and ALL-L2 (Precursor B or T cell) type, were eligible for study, Demographic, clinical, and laboratory data of ALL patients at presentation and at the end of induction were reviewed. Results: Of a total 240 ALL patients, only 221 of them participated in the study and underwent to the analysis. M:F ratio =1.3:1, (1-9.9) years, were more predominant age group. About two third of the patients were standard risk group. 91.4% of the patients with Precursor B cell ALL (PBC ALL). 4.8% of patients with initial CNS involvement, 85.5% (n 189/221) of patients completed induction therapy and reached 1st complete remission (CR1), while 11.3%(n 25/221), were died . The most common cause of induction death was infection (72%) Conclusion: The early outcome for children with ALL at end of induction therapy was suboptimal, while slightly high percent of induction death with some patients abandoned treatment; only 85.5% survived the induction phase